MARKET

VIR

VIR

Vir Biotechnology, Inc.
NASDAQ
5.93
-0.21
-3.42%
After Hours: 6.00 +0.07 +1.18% 19:27 12/18 EST
OPEN
6.20
PREV CLOSE
6.14
HIGH
6.33
LOW
5.92
VOLUME
2.10M
TURNOVER
--
52 WEEK HIGH
14.45
52 WEEK LOW
4.155
MARKET CAP
825.01M
P/E (TTM)
-1.6381
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on Top Healthcare Stocks: Neurocrine (NBIX), Vir Biotechnology (VIR)
TipRanks · 1d ago
Vir Biotechnology: Strong HDV Performance and Strategic Partnership Drive Buy Rating
TipRanks · 1d ago
Strategic Partnership Enhances Vir Biotechnology’s Financial Outlook and European Market Opportunities
TipRanks · 1d ago
Closing Bell Movers: Lennar slips 4% after Q4 miss
TipRanks · 2d ago
Pliant Therapeutics Appoints Minnie Kuo as Chief Operating Officer
Reuters · 2d ago
Vir Biotechnology issues license to Norgine to market hepatitis D candidate
Seeking Alpha · 2d ago
Vir Biotechnology Secures Licensing Deal with Norgine
TipRanks · 2d ago
Vir Biotechnology to Grant Exclusive License for Chronic Hepatitis Treatment to Norgine
Dow Jones · 2d ago
More
About VIR
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.

Webull offers Vir Biotechnology Inc stock information, including NASDAQ: VIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VIR stock methods without spending real money on the virtual paper trading platform.